BMO Capital Markets has lifted its price target on Novo Nordisk's New York-listed shares to $47 from $45, following the Danish drugmaker's second-quarter results. The bank also raised its 2026 earnings-per-share estimate to 23.26 Danish kroner from 19.43 kroner, reflecting greater optimism about the near-term earnings power of Wegovy, its blockbuster obesity treatment.
But the upgrade comes with a caveat: BMO wants to see a clearer long-term growth plan from the company, especially as it navigates pricing pressures in the US market. The bank is holding off on a more decisive stance until Novo Nordisk hosts its Capital Markets Day in September, where management is expected to outline its strategy for the coming years.
What's driving the optimism?
Novo Nordisk has been at the center of the booming market for GLP-1 drugs, which are used to treat obesity and type 2 diabetes. Wegovy, in particular, has become a household name, and sales have surged as demand continues to outpace supply. That momentum was evident in the company's second-quarter results, which prompted BMO to bump up its earnings forecast for 2026.
The revised EPS estimate suggests BMO sees stronger profit growth ahead, driven by Wegovy's continued expansion and the company's broader portfolio. However, the bank also pointed to pricing headwinds in the US, where competition is intensifying and insurers are pushing back on the high list prices of these drugs. This could limit how much of the revenue growth actually translates into bottom-line profit.
Why pricing matters
For everyday investors, pricing headwinds are a key factor to watch. When a drugmaker faces pressure on prices, it can squeeze profit margins even if sales volumes are rising. In the case of Novo Nordisk, the US market is crucial—it's the largest market for GLP-1 drugs, and any pricing concessions could have a significant impact on the company's financials.
BMO's caution reflects a broader concern across the pharmaceutical sector: as blockbuster drugs face increasing scrutiny over their cost, companies may need to adjust their pricing strategies. This can affect not only Novo Nordisk but also other players in the GLP-1 space, such as Eli Lilly, which competes with Wegovy through its own obesity drug, Zepbound.
What to watch at Capital Markets Day
Investors will be looking for more than just a reaffirmation of existing targets at the September Capital Markets Day. BMO wants to see a detailed roadmap for how Novo Nordisk plans to sustain growth beyond the current wave of GLP-1 demand. That could include updates on pipeline drugs, manufacturing capacity expansions, and strategies to defend its market share as competition heats up.
The event is also an opportunity for management to address the pricing concerns directly. If the company can articulate a plan to mitigate US pricing pressure while maintaining growth, it could reassure investors and potentially lead to further analyst upgrades.
What it means for investors
For individual investors, the key takeaway is that BMO's target raise is a positive signal, but it's not a ringing endorsement. The bank is essentially saying: 'We see good near-term earnings, but we need more clarity on the long-term story.' That's a common stance when a company is growing fast but faces structural challenges.
It's also worth noting that analyst price targets are just one piece of the puzzle. They reflect a single firm's view and can change quickly based on new information. Investors should consider the broader picture, including the competitive landscape, regulatory environment, and the company's own guidance.
Novo Nordisk's situation is reminiscent of other high-growth companies that have seen their valuations swing on news about pricing or competition. For example, GLP-1 users are also boosting sales for other companies, like Glanbia, which recently lifted its profit outlook on the back of increased protein sales. That shows the ripple effects of the GLP-1 boom across different sectors.
Meanwhile, the broader market has been watching how drugmakers handle pricing pressures. Other companies have also raised their targets after strong quarters, but the sustainability of those targets often depends on external factors like pricing and competition.
As September approaches, investors will be listening closely to what Novo Nordisk's management says. The Capital Markets Day could be a catalyst for the stock, either reinforcing confidence or raising new questions. Until then, BMO's move suggests a cautious optimism—acknowledging the company's strengths while waiting for more clarity on the path ahead.
